These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38918102)

  • 1. Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.
    Lin M; Deng JZ; Scapin G; Yuan Y; Gomez-Llorente Y; Tong W; Porambo R; Kong J; Ikemoto N; Lancaster C; Kaelber J; Winters M; Zhuang P
    Vaccine; 2024 Nov; 42(25):126067. PubMed ID: 38918102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections.
    Deng JZ; Lancaster C; Winters MA; Phillips KM; Zhuang P; Ha S
    Vaccine; 2022 Mar; 40(10):1464-1471. PubMed ID: 35140014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
    Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of structural modification induced activation of pneumococcal polysaccharide by GC-MS for the conjugate vaccine.
    Shende N; Karale A; Bore P; Bhagade S; Gulhane A; Mallya AD; Dhere RM
    Carbohydr Res; 2023 Sep; 531():108878. PubMed ID: 37390792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of pneumococcal serotype 7F in vaccine conjugation.
    Deng JZ; Jia X; Zong C; He J; Ha S; Zhuang P
    Glycoconj J; 2023 Oct; 40(5):565-573. PubMed ID: 37402017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
    Fairman J; Agarwal P; Barbanel S; Behrens C; Berges A; Burky J; Davey P; Fernsten P; Grainger C; Guo S; Iki S; Iverson M; Kane M; Kapoor N; Marcq O; Migone TS; Sauer P; Wassil J
    Vaccine; 2021 May; 39(23):3197-3206. PubMed ID: 33965258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of High Molecular Weight Pneumococcal Conjugate by SEC-MALS and AF4-MALS.
    Deng JZ; Lin J; Chen M; Lancaster C; Zhuang P
    Polymers (Basel); 2022 Sep; 14(18):. PubMed ID: 36145915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for
    Turner AEB; Gerson JE; So HY; Krasznai DJ; St Hilaire AJ; Gerson DF
    Synth Syst Biotechnol; 2017 Mar; 2(1):49-58. PubMed ID: 29062961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Smith WJ; Thompson R; Egan PM; Zhang Y; Indrawati L; Skinner JM; Blue JT; Winters MA
    Vaccine; 2023 Aug; 41(35):5113-5125. PubMed ID: 37321893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response.
    Perciani CT; Barazzone GC; Goulart C; Carvalho E; Cabrera-Crespo J; Gonçalves VM; Leite LC; Tanizaki MM
    Clin Vaccine Immunol; 2013 Jun; 20(6):858-66. PubMed ID: 23554468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-phthalaldehyde based quantification of polysaccharide modification in conjugate vaccines.
    Rajendar B; Reddy MVNJ; Suresh CNV; Rao GS; Matur RV
    J Pharm Biomed Anal; 2024 Apr; 241():115995. PubMed ID: 38309096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugate of structurally reassigned pneumococcal serotype 31 polysaccharide with CRM197 elicited potent immune response.
    Sun T; Mai S; Mao H; Li H; Duan Y; Meng S; Bao J; Ding N; Zong C
    Carbohydr Polym; 2022 Aug; 289():119414. PubMed ID: 35483835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era.
    Mohamed OE; Williams L; Wong GK; Hayes M; Townsend K; Harding S; Huissoon AP
    J Immunol Methods; 2020 Nov; 486():112846. PubMed ID: 32882318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual polysaccharide quantification in polyvalent pneumococcal conjugate vaccine using rate nephelometry.
    Rajendar B; Pydigummala JS; Rao GS; Chigurambotla R; Matur RV
    J Immunol Methods; 2023 Oct; 521():113539. PubMed ID: 37595680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines.
    Poolman J; Frasch C; Nurkka A; Käyhty H; Biemans R; Schuerman L
    Clin Vaccine Immunol; 2011 Feb; 18(2):327-36. PubMed ID: 21123523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcus pneumoniae serotype 15B polysaccharide conjugate elicits a cross-functional immune response against serotype 15C but not 15A.
    Hao L; Kuttel MM; Ravenscroft N; Thompson A; Prasad AK; Gangolli S; Tan C; Cooper D; Watson W; Liberator P; Pride MW; Jansen KU; Anderson AS; Scully IL
    Vaccine; 2022 Aug; 40(33):4872-4880. PubMed ID: 35810060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.